Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 55.11

-2.6%

Nov 7 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Biomaven who wrote (5983)	3/20/2002 9:22:31 PM
From: aknahow	Read Replies (1) of 52153

This is the source I used to claim the news was old. Such a logical case was made I knew in my heart it was a correct analysis. Besides PDLI collapsed about the same time which made me even more convinced. Know one should not rely on inter-net post but I trust the original source even if he was quoting someone else. From: gwohanka Date: Tue Feb 19, 2002 2:57 pm Subject: Borrowed from S.I. To:Ian Stromberg who wrote (5715)<br> From: Biomaven <br> Tuesday, Feb 19, 2002 5:38 PM<br> Respond to of 5718 <br><br><br> <PDLI><br><br> I've now seen the Cowen report (thanks, S!). They acknowledge that the trial is not unblinded, but say that their conversations with doctors<br> who treated an estimated 20-25% of the patients in the trial lead them to believe it won't be successful, particularly in view of the other<br> promising new drugs on the horizon.<br><br> Note that the trial was vs. placebo in patients first treated with cyclosporine. The relapse rate from cyclosporine is well known, so it seems<br> somewhat credible to me that the doctors could in fact tell without unblinding.<br><br> Sure would be nice to get some good news for a change...<br><br> Peter

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next